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PLowering Glucose to Prevent Adverse
Cardiovascular Outcomes in a Critical Care Setting
Antonio Ceriello, MD,* Stuart W. Zarich, MD,† Roberto Testa, MD‡
Coventry, United Kingdom; Bridgeport, Connecticut; and Ancona, Italy
High admission blood glucose levels after acute myocardial infarction are common and associated with an in-
creased risk of death in patients with or without diabetes. Hyperglycemia is associated with altered myocardial
blood flow and energetics and can lead to a pro-oxidative/proinflammatory state. The use of intensive insulin
treatment has shown superior benefits in the treatment of hyperglycemia versus glucose-insulin-potassium infu-
sion, particularly in critical care settings. (J Am Coll Cardiol 2009;53:S9–13) © 2009 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.054m
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in recent years, attention has been given to evidence that in
atients admitted to the intensive care unit (ICU) with
cute coronary syndrome (ACS), hyperglycemia is associ-
ted with an increased risk of mortality and morbidity, in
he presence or absence of a history of diabetes (1).
requently in medicine, the “new” discovery of an old
nding occurs; hyperglycemia in ACS is one of these cases.
n unusually high prevalence of glycosuria in acute myo-
ardial infarction (AMI) patients without diabetes was
oted as early as 1931 (2). However, the observation that
asting blood glucose levels shortly after myocardial infarc-
ion are a better guide to prognosis was not reported until
975 (3). Associations linking hyperglycemia during ACS
nd subsequent mortality were reported in 1987 (4) and
onfirmed in 1989 (5), 1991 (6), and 1993 (7). A large
eta-analysis by Capes et al. (1) in 2000 further addressed
his issue, adding to the evidence that lowering glucose
ecreases mortality in patients with diabetes in the presence
f ACS (8). This meta-analysis of 15 cohort studies and
linical trials involving 1,856 patients without diabetes
ospitalized for AMI found that those with blood glucose
evels 110 to 144 mg/dl had a 3.9-fold (95% confidence
nterval [CI]: 2.9 to 5.4) greater risk of death than those
ith lower levels. Those with glucose levels 144 to 180
g/dl were also at increased risk for heart failure and
ardiogenic shock (1).
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008, accepted September 23, 2008.In some cases, the elevation of glucose could simply be a
arker of pre-existing, but not yet detected, type 2 diabetes
ellitus (T2DM) or impaired glucose tolerance (9).
orhammar et al. (9) reported on a cohort with a mean age
f 63.5  9 years and a mean blood glucose concentration
t admission of 117 mg/dl. The mean 2-h post-load blood
lucose concentration was 166 mg/dl at hospital discharge,
nd 162 mg/dl 3 months later. The numbers of individuals
ho had impaired glucose tolerance at discharge and after 3
onths were 58 of 164 (35%, 95% CI: 28% to 43%) and 58
f 144 (40%, 95% CI: 32% to 48%), respectively, and those
ith previously undiagnosed T2DM were 51 of 164 (31%,
5% CI: 24% to 38%) and 36 of 144 (25%, 95% CI: 18% to
2%). Independent predictors of abnormal glucose tolerance
t 3 months were concentrations of hemoglobin A1C at
dmission (p  0.024) and fasting blood glucose concen-
rations 4 days after admission (p  0.044). These results
uggested that previously undiagnosed diabetes and impaired
lucose tolerance were common in patients with AMI and that
hese abnormalities may be detected early. A positive associa-
ion between hyperglycemia at the time of the event and
ubsequent mortality from ACS, even in patients without
iabetes, has been frequently and recently confirmed (10–13).
actors Contributing to Poor Prognosis
lthough stress hyperglycemia correlates well with progno-
is in ACS, the correlation between admission glucose levels
nd infarct size, as measured by myocardial enzyme release,
as not been universal (11). Thus, excessive stress-mediated
elease of counter-regulatory hormones (i.e., catecholamines,
lucagon, and cortisol) caused by a greater degree of myocar-
ial damage cannot fully account for the extent of hyperglyce-
ia in ACS. Other pathophysiological mechanisms involved
n the excess mortality in patients with AMI and acute
yperglycemia need to be identified. The links among
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tes, and cardiovascular (CV) dis-
ease may help us to better un-
derstand both the prevalence
of hyperglycemia in ACS and
the association of hyperglyce-
mia with adverse CV outcomes.
Insulin-resistant patients with
ACS are more prone to hyper-
glycemia in the setting of acute
stress caused by relative insuli-
nopenia, which is mediated, in
part, by a decrease in pancreatic
beta-cell function and increased
hepatic glycogenolysis, as well as
insulin resistance exacerbated by
increased free fatty acid (FFA)
levels (14). Insulin resistance is
associated with a host of tradi-
tional (i.e., obesity, hypertension,
glucose intolerance, microalbu-
minuria, and atherogenic dyslip-
idemia) and novel (i.e., endothe-
ial dysfunction and proinflammatory, pro-oxidative, and
rothrombotic states characterized by abnormal levels of
irculating adhesion molecules, cytokines, and adipokines,
uch as adiponectin) CV risk factors. These same factors are
lso associated with increased CV events, as well as an
dverse prognosis in ACS.
In the San Antonio Heart Study, high levels of insulin
esistance were associated with a 2.5-fold increased risk of
eveloping CV events (15). Interestingly, after adjusting for
1 known CV risk factors, insulin-resistant subjects still had
2-fold increased risk of CV disease. Thus, insulin resis-
ance was associated with excess CV risk independent of
ssociated metabolic risk factors.
Additionally, acute hyperglycemia is associated with ad-
erse metabolic effects that may contribute to a poor
utcome in ACS. Although glucose metabolism is a major
yocardial energy source, it is important to recognize that
xidation of FFAs is the preferred source of energy in the
esting aerobic state. Myocardial ischemia results in an
ncreased rate of glycogen breakdown and glucose uptake via
ranslocation of glucose transporter-4 receptors to the sar-
olemma (16). This adaptive mechanism is important be-
ause glucose oxidation requires less oxygen than FFA
xidation to maintain adenosine triphosphate (ATP) pro-
uction. Thus, myocardial energetics are more efficient
uring the increased dependence on glucose oxidation with
schemia. With relative insulinopenia (insulin resistance or
rank diabetes) exacerbated by the stress of ACS, the
schemic myocardium is forced to utilize FFAs more than
lucose for an energy source because myocardial glucose
ptake is acutely impaired. Thus, despite acute hyperglyce-
ia, a metabolic crisis may ensue as the hypoxic myocar-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
AMI  acute myocardial
infarction
ATP  adenosine
triphosphate
CABG  coronary artery
bypass grafting
CI  confidence interval
CV  cardiovascular
FFA  free fatty acid
GIK  glucose-insulin-
potassium
ICU  intensive care unit
SPRINT  Specialized
Relative Insulin and
Nutrition Tables
T2DM  type 2 diabetes
mellitusium becomes less energy efficient in the setting of frank hiabetes or insulin resistance, as FFA oxidation results in
he generation of fewer ATP molecules per molecule of
xygen as compared with glucose oxidation. Catecholamine
elease with stress further stimulates the release of FFAs,
hich may contribute to myocardial damage and arrhythmia
isk by increasing oxygen demand and oxidative stress
17,18).
The adverse effects of acute hyperglycemia may also be, in
art, attributable to the direct effects of elevated glucose
evels on the blood vessel wall and on platelet function,
hich are discussed by Dandona et al. (19) elsewhere in this
upplement.
nsulin Treatment in the ICU:
eed for a Standard Validated Algorithm
ight glycemic control is an important issue in the man-
gement of ICU patients and in particular to the cardiolo-
ist. The glycemic goals described by Van den Berghe et al.
20) in their landmark study of intensive insulin therapy
eem difficult to achieve in the ICU setting. Many CV
pecialists are concerned about the increased frequency of
evere hypoglycemic episodes with more stringent glycemic
ontrol, and several protocols have been proposed to address
hese concerns. A recent small observational study evaluated
dherence, efficacy, and safety of an insulin protocol for
ritically ill patients with target blood glucose levels between
1 and 110 mg/dl; factors associated with adequate daily
lood glucose control were also examined (21). Blood
lucose measurements were obtained during 352 protocol
mplementation days; with 71% adherence, glucose levels
ere within the desired range 42% of the time, and 60% of
atients experienced at least 1 hypoglycemic event. Adher-
nce to the protocol (p  0.001), high bilirubin level (p 
.001), low daily insulin dose (p  0.002), and low
-reactive protein level (p  0.048) were independently
ssociated with adequate daily blood glucose control. Pro-
ocol adherence was positively associated with daily time in
he target range; however, efficacy during the total protocol
mplementation time remained poor. Because of the fre-
uency of hypoglycemia, the investigators suggest that
rotocols to maintain blood glucose levels between 81 and
10 mg/dl in critically ill patients may not be recommended
21). Although this position is in the minority, it reflects the
ack of consensus regarding the aim of insulin therapy; CV
pecialists must weigh the risk of hypoglycemia against the
mportance of obtaining good glycemic control.
Although hypoglycemia is unlikely to influence CV
utcomes (22–24), a consensus regarding a universal stan-
ard insulin protocol has not been reached. The Specialized
elative Insulin and Nutrition Tables (SPRINT) protocol is
simple alternative ICU protocol for modulating insulin
nd nutritional input to gain tight blood glucose control in
he 72 to 110 mg/dl target band (25). The tables were used
y nurses to determine glycemic control actions based on
ourly or 2-h blood glucose measurements and nutrition
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February 3, 2009:S9–13 Acute Hyperglycemia in Critical Care Settingsnd insulin administration rates. A pilot study using the
PRINT protocol was conducted, observing 2,152 h of
lood glucose level control. Results showed that the patient
ohort average Acute Physiology and Chronic Health Eval-
ation II score, a classification system to assess severity of
isease, was higher compared with previous intensive insulin
linical studies (25). Overall, 64% of measurements were in
he 72 to 110 mg/dl band, 89% in the 72 to 126 mg/dl band,
nd 96% in the 72 to 140 mg/dl band, with an average value
f 105 mg/dl. Only 1.4% of all measurements were 72
g/dl, with a minimum value of 58 mg/dl and a maximum
alue of 213 mg/dl. Glucose control was achieved using the
PRINT protocol, the results of which led to a high level of
upport and acceptance of frequent measurements required
or effective glucose control. Moreover, because the protocol
as easy to implement, minimal noncompliance by the
linical staff resulted (25).
The feasibility of insulin infusion therapy has been recently
upported by a review of published trials using insulin/glucose
lgorithms in critically ill patients (26). Nine recent studies
ere conducted in the ICU, 9 other studies were con-
ucted in the perioperative setting, and 6 studies were
onducted in patients with AMI or stroke. Studies
onducted before 2001 did not include normoglycemia
mong their aims. This changed after the landmark study
y Van den Berghe et al. (27) in 2001, and glycemic goals
ecame tighter, with a target range between 72 and 144
g/dl in most subsequent studies. The use of a dynamic
cale protocol with tight glucose targets and 2 blood
lucose values to determine the insulin infusion rate
eemed to yield the best results in terms of glycemic
ontrol and fewer hypoglycemic episodes (26).
herapeutic Prospects/Options
ecause glucose exerts several direct and powerfully dam-
ging effects, all capable of worsening prognosis after ACS,
mportant questions for CV specialists remain: 1) Should
yperglycemia, in the presence of ACS, be treated with
lucose-insulin-potassium (GIK)? 2) Should hyperglyce-
ia in ACS be treated with intensive insulin therapy
lone? 3) How should hyperglycemia in ACS be treated
n patients without diabetes?
vidence From Critical Care Settings
trong support for tight glycemic control as a key strategy
or improving prognosis after ACS comes from the study by
an den Berghe et al. (27). This prospective trial studied
,548 patients in a surgical ICU who stayed more than 5
ays. One-half of the patients were infused with insulin and
hus rendered relatively euglycemic (fasting blood glucose
0 to 110 mg/dl). A reduction in total mortality (48%),
ncidence of bacteremia (46%), renal failure requiring dial-
sis (41%), intensive care neuropathy (44%), and the need
or red blood cell transfusion (50%) occurred, compared
ith control subjects. Moreover, the need for mechanical Qentilation and intensive care was also reduced in these
atients (27). These results highlighted the message that
utcomes, which improve with low-dose insulin infusion,
re more dependent on the reduction in plasma glucose
evels than on the dose of insulin administered (28).
In a prospective study designed to reduce and maintain
lucose concentrations 110 mg/dl in a medical ICU
opulation requiring admission for 3 days, insulin therapy
educed mortality by 18% and reduced the duration of
echanical ventilation and incidence of renal injury com-
ared with control subjects (20). Other benefits included a
eduction in the length of stay in the ICU and the hospital.
hese findings were consistent with an observation by
rinsley (29) in a similar setting, the medical ICU of a
ommunity teaching hospital.
vidence From ACS Trials
number of recent clinical trials of insulin therapy in the
etting of ACS have been conducted (Table 1) (30–36).
eduction in mortality was not consistently shown. How-
ver, in 1 of these trials (36), subgroup analysis showed a
eduction in C-reactive protein in patients receiving insulin
herapy (37). The investigators reported that in patients
ith or without known diabetes with hyperglycemia during
I, it is important to maintain normoglycemia with insulin
nfusion in the first 24 h during MI, which tends to be
ccompanied by a significantly smaller increase of C-reactive
rotein. Interestingly, the investigators found a positive
orrelation between mean glucose levels during the first 24 h
nd serum C-reactive protein levels 2 days after admission.
owever, this correlation was found only when the control
nd treatment groups were pooled; no correlation was found
ith the insulin dose. Therefore, although this report is of
reat interest, the question regarding the major usefulness of
nsulin infusion versus tight glycemic control was not
nswered (38).
Finally, another recent study using GIK infusion at the
ime of reperfusion with thrombolytic agents (3 h after chest
ain) showed an 88% reduction in major CV events at 1 year
39). However, these results require more study.
vidence From Cardiac Surgery
he importance of reducing glucose concentrations in
atients undergoing coronary artery bypass grafting
CABG) has been shown in retrospective and prospective
ontrolled studies by Furnary et al. (40) and Lazar et al.
41,42). Furnary et al. (40) showed that with improved
lycemia (reducing glucose concentrations from 213 to 177
g/dl), there is a reduction in mortality (from 5.3% to
.5%), and that insulin infusion is independently protective
gainst death. Similarly, Lazar et al. (41,42) showed that the
aintenance of improved glycemia with insulin infusion
eads to reductions in mortality, cardiac failure, and arrhyth-
ias in patients undergoing CABG. A randomized trial by
uinn et al. (43) in patients without T2DM undergoing
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Acute Hyperglycemia in Critical Care Settings February 3, 2009:S9–13ABG with GIK therapy showed better myocardial func-
ion, decreased incidence of low cardiac output, and a
eduction in myocardial injury.
urrent Guidelines
hile recognizing that the relationship between hypergly-
emia and adverse ACS outcomes needs clarification, the
merican Heart Association Diabetes Committee, in a
ecent scientific statement, offered general recommenda-
ions for clinicians (44). During hospitalization, glucose
evels should be measured in all patients with suspected or
onfirmed ACS as part of the initial laboratory evaluation
Level of Evidence: A). Glucose levels should be monitored
losely in patients with ACS admitted to an ICU (Level of
vidence: B) and intensive glucose control considered when
ignificant hyperglycemia (plasma glucose 180 mg/dl) is
resent (Level of Evidence: B); intravenous insulin is
ecommended for controlling glucose in ICU patients
Level of Evidence: B). In hospitalized patients with ACS
nd hyperglycemia but no prior diabetes history, the severity
f their metabolic derangements should be evaluated (Level
f Evidence: B). All patients with ACS and established
iabetes, newly diagnosed diabetes, or evidence of insulin
esistance should have an outpatient glucose control plan
etermined before discharge (Level of Evidence: C). Addi-
ional specific, evidence-based recommendations can be
ade as the gaps in the understanding of the hyperglycemia–
CS adverse outcomes relationship are addressed.
onclusions
yperglycemia is associated with a graded increased risk of
V events. It is important for cardiology specialists to
ajor Trials of Insulin Therapy in ACS
Table 1 Major Trials of Insulin Therapy in ACS
Study (Year) (Ref. #) N
GIK
CREATE-ECLA (2005) (34) 20,201 STEMI (18% with T2DM) IV GIK 24 h us
OASIS-6 (2006) (35) 2,748 STEMI (15% with T2DM) IV GIK 24 h vs.
OASIS-6/CREATE-ECLA
pooled (2006) (34,35)
22,943 STEMI IV GIK 24 h vs.
Insulin/glucose
DIGAMI 1 (1995) (30) 620 ACS with diabetes IV insulin/gluco
vs. standard
DIGAMI 2 (2005) (33) 1,235 ACS with T2DM 1: IV insulin/gl
2: IV insulin/
Insulin/dextrose
HI-5 (2006) (36) 240 STEMI with diabetes or
admission glucose
140 mg/dl
IV insulin/dext
CS acute coronary syndrome; CREATE-ECLAClinical Trial of Reviparin andMetabolicModulation in
ellitus Insulin-Glucose Infusion in Acute Myocardial Infarction; GIK  glucose-insulin-potassium; HI-5
rganization for the Assessment of Strategies for Ischemic Syndromes; SC subcutaneous; STEMI ecognize that in patients with ACS, admission hypergly-emia has been linked both to increased early and to
ncreased late mortality. Intensive glucose control in the
ospital lowers the risk of mortality in critically ill patients.
linical trials suggest that intensive glucose control lowers
V risk and clearly lowers the risk of renal disease.
tandardized protocols are necessary that effectively achieve
nd maintain glucose levels within a given range and with
inimal risk of hypoglycemia. Clear evidence to date shows
hat protocols using GIK therapy do not control glucose
evels and do not lower mortality.
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